MAP logo

Microba Life Sciences Limited Stock Price

ASX:MAP Community·AU$42.6m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 4 Fair Values set on narratives written by author

MAP Share Price Performance

AU$0.07
-0.10 (-58.82%)
AU$0.07
-0.10 (-58.82%)
Price AU$0.07

MAP Community Narratives

There are no narratives available yet.

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks
1 Reward

Microba Life Sciences Limited Key Details

AU$15.7m

Revenue

AU$8.2m

Cost of Revenue

AU$7.4m

Gross Profit

AU$22.4m

Other Expenses

-AU$14.9m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-0.025
47.49%
-95.34%
3.7%
View Full Analysis

About MAP

Founded
2017
Employees
n/a
CEO
Luke Reid
WebsiteView website
microba.com

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; MetaXplore that provides a range of diagnostics solution under the Co-Biome brand; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, and inflammatory bowel and autoimmune diseases, as well as microbiome databank. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.

Recent MAP News & Updates

Recent updates

No updates